InsiderTrades.com logo
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

CYCC Insider Trading (Cyclacel Pharmaceuticals)

Insider Ownership Percentage: 1.08%
Insider Buying (Last 12 Months): $18,000.00
Insider Selling (Last 12 Months): $42.84

Cyclacel Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Cyclacel Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclacel Pharmaceuticals Share Price & Price History

Current Price: $1.85
Price Change: ▲ Price Increase of +0.27 (17.09%)
As of 08/16/2022 01:00 AM ET

This chart shows the closing price history over time for CYCC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Tailor an Options Trading Strategy to Fit Your Needs
From RJO Futures   |   Ad
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.
pixel

Cyclacel Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2021Sam L. BarkerDirectorSell12$3.57$42.84View SEC Filing Icon  
11/18/2021Spiro George RombotisCEOBuy4,000$4.50$18,000.00View SEC Filing Icon  
See Full Table
A One Stop Shop for Everything Futures Trading
From RJO Futures   |   Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
pixel

SEC Filings (Institutional Ownership Changes) for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

32.41% of Cyclacel Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CYCC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Cyclacel Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2022Millennium Management LLC104,443$0.11M0.0%N/A1.045%Search for SEC Filing on Google Icon
8/15/2022Sio Capital Management LLC454,355$0.49M0.2%+7.5%4.546%Search for SEC Filing on Google Icon
8/13/2022Virtu Financial LLC30,616$33K0.0%N/A0.306%Search for SEC Filing on Google Icon
8/13/2022Renaissance Technologies LLC63,000$68K0.0%N/A0.630%Search for SEC Filing on Google Icon
2/10/2022Acadian Asset Management LLC23,242$89K0.0%N/A0.233%Search for SEC Filing on Google Icon
11/16/2021Two Sigma Advisers LP121,500$0.64M0.0%+929.7%1.316%Search for SEC Filing on Google Icon
11/15/2021Pura Vida Investments LLC105,141$0.55M0.0%-33.2%1.139%Search for SEC Filing on Google Icon
11/15/2021Tri Locum Partners LP522,943$2.76M1.1%+66.9%5.663%Search for SEC Filing on Google Icon
11/12/2021Affinity Asset Advisors LLC400,000$2.11M0.5%+5.3%4.332%Search for SEC Filing on Google Icon
11/2/2021Raymond James Financial Services Advisors Inc.10,006$53K0.0%-83.3%0.108%Search for SEC Filing on Google Icon
10/15/2021NEXT Financial Group Inc14,752$77K0.0%+70.0%0.160%Search for SEC Filing on Google Icon
8/18/2021Ikarian Capital LLC100,000$0.59M0.0%-66.7%1.083%Search for SEC Filing on Google Icon
8/17/2021Boothbay Fund Management LLC10,545$62K0.0%-66.7%0.114%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC250,797$1.49M0.0%-14.7%2.716%Search for SEC Filing on Google Icon
8/16/2021Tri Locum Partners LP313,331$1.86M0.6%+6.8%3.393%Search for SEC Filing on Google Icon
8/16/2021Schonfeld Strategic Advisors LLC102,525$0.61M0.0%-25.0%1.110%Search for SEC Filing on Google Icon
8/16/2021Maven Securities LTD234,500$1.43M0.1%-6.2%2.540%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp14,957$89K0.0%N/A0.162%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC50,860$0.30M0.0%+143.3%0.551%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.327,658$1.94M0.0%+9.2%3.548%Search for SEC Filing on Google Icon
7/31/2021NEXT Financial Group Inc8,680$51K0.0%N/A0.094%Search for SEC Filing on Google Icon
5/19/2021Virtu Financial LLC13,108$93K0.0%+27.3%0.142%Search for SEC Filing on Google Icon
5/19/2021Squarepoint Ops LLC23,836$0.17M0.0%N/A0.258%Search for SEC Filing on Google Icon
5/18/2021Point72 Asset Management L.P.230,000$1.64M0.0%N/A2.491%Search for SEC Filing on Google Icon
5/18/2021Verition Fund Management LLC116,674$0.83M0.0%N/A1.264%Search for SEC Filing on Google Icon
5/18/2021Morgan Stanley100,000$0.71M0.0%-13.0%1.083%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC293,867$2.09M0.0%N/A3.182%Search for SEC Filing on Google Icon
5/18/2021Silverarc Capital Management LLC250,000$1.78M1.0%N/A2.707%Search for SEC Filing on Google Icon
5/17/2021Schonfeld Strategic Advisors LLC136,725$0.97M0.0%N/A1.481%Search for SEC Filing on Google Icon
5/17/2021Sphera Funds Management LTD.508,322$3.61M0.3%N/A5.505%Search for SEC Filing on Google Icon
5/17/2021Ikarian Capital LLC300,000$2.13M0.1%-23.4%3.249%Search for SEC Filing on Google Icon
5/12/2021Geode Capital Management LLC20,904$0.15M0.0%N/A0.226%Search for SEC Filing on Google Icon
5/12/2021Pura Vida Investments LLC273,958$1.95M0.1%-42.3%2.967%Search for SEC Filing on Google Icon
5/11/2021Acadian Asset Management LLC34,057$0.24M0.0%N/A0.369%Search for SEC Filing on Google Icon
4/12/2021Valeo Financial Advisors LLC4,500$32K0.0%N/A0.063%Search for SEC Filing on Google Icon
2/24/2021Virtu Financial LLC10,293$80K0.0%N/A0.212%Search for SEC Filing on Google Icon
2/16/2021Pura Vida Investments LLC475,000$3.71M0.1%N/A9.766%Search for SEC Filing on Google Icon
2/16/2021Acuta Capital Partners LLC150,000$1.17M0.3%N/A3.084%Search for SEC Filing on Google Icon
2/12/2021Raymond James Financial Services Advisors Inc.57,006$0.45M0.0%+24.6%1.172%Search for SEC Filing on Google Icon
2/12/2021Ikarian Capital LLC391,450$3.06M0.1%N/A8.048%Search for SEC Filing on Google Icon
11/4/2020Raymond James Financial Services Advisors Inc.45,756$0.17M0.0%+48.8%0.941%Search for SEC Filing on Google Icon
7/17/2020Raymond James Financial Services Advisors Inc.30,756$0.14M0.0%-48.8%0.633%Search for SEC Filing on Google Icon
7/16/2020Wedbush Securities Inc.29,300$0.14M0.0%N/A0.603%Search for SEC Filing on Google Icon
2/13/2020Renaissance Technologies LLC1,269,326$0.85M0.0%+8.4%7.380%Search for SEC Filing on Google Icon
2/12/2020Raymond James Financial Services Advisors Inc.60,125$40K0.0%-20.0%0.350%Search for SEC Filing on Google Icon
2/4/2020Virtu Financial LLC50,232$34K0.0%+90.3%0.292%Search for SEC Filing on Google Icon
8/12/2019Renaissance Technologies LLC1,102,400$0.60M0.0%+82.5%6.409%Search for SEC Filing on Google Icon
8/13/2018Renaissance Technologies LLC91,400$0.13M0.0%+513.4%0.762%Search for SEC Filing on Google Icon
2/14/2018Two Sigma Investments LP70,310$0.12M0.0%N/A0.591%Search for SEC Filing on Google Icon
2/9/2018Citadel Advisors LLC61,900$0.11M0.0%N/A0.520%Search for SEC Filing on Google Icon
2/9/2018Virtu Financial LLC199,464$0.35M0.0%+69.5%1.676%Search for SEC Filing on Google Icon
8/14/2017Tang Capital Management LLC559,900$2.11M0.7%No Change0.000%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Cyclacel Pharmaceuticals logo
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Read More on Cyclacel Pharmaceuticals

Today's Range

Now: $1.85
Low: $1.52
High: $1.86

50 Day Range

MA: $1.27
Low: $1.08
High: $1.85

52 Week Range

Now: $1.85
Low: $1.01
High: $6.10

Volume

2,561,767 shs

Average Volume

1,731,051 shs

Market Capitalization

$23.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Who are the company insiders with the largest holdings of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' top insider investors include:
  1. Sam L Barker (Director)
  2. Spiro George Rombotis (CEO)
Learn More about top insider investors at Cyclacel Pharmaceuticals.

Who are the major institutional investors of Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' top institutional shareholders include:
  1. Sio Capital Management LLC — 4.55%
  2. Millennium Management LLC — 1.04%
  3. Renaissance Technologies LLC — 0.63%
  4. Virtu Financial LLC — 0.31%
Learn More about top institutional investors of Cyclacel Pharmaceuticals stock.

Which major investors are buying Cyclacel Pharmaceuticals stock?

In the last quarter, CYCC stock was acquired by institutional investors including:
  1. Millennium Management LLC
  2. Renaissance Technologies LLC
  3. Sio Capital Management LLC
  4. Virtu Financial LLC
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel